Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA and PET-oriented therapy with acalabrutinib-R-CHOP in DLBCL
2020-003876-42Phase 2Active
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of acalabrutinib in diffuse large B-cell lymphoma (DLBCL) (3 cohorts), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Progression-free survival (PFS). Started Jan 2022; status: active.
02
Drugs
acalabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2020-003876-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003876-42.